PharmacoKINEtics of TAMoxifen and Its Metabolites in Breast Cancer Patients: the Influence of a Dose Increase in Phenotypic Poor Metabolizers of CYP2D6 (KINETAM)

NCT01192308 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
42
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Radboud University Medical Center